Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21974553 | 1.00 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1AMAPTBLM | |
| SCHEMBL195816 | 1.00 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1AMAPTBLM | |
| SCHEMBL22205226 | 1.00 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1AMAPTBLM | |
| SCHEMBL16053327 | 1.00 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1AMAPTBLM | |
| SCHEMBL19899224 | 1.00 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1AMAPTBLM | |
| SCHEMBL13147621 | 1.00 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1AMAPTBLM | |
| SCHEMBL22205224 | 1.00 | CYP19A1 (0.40) | CYP19A1ADRA2AADRA1AMAPTBLM | |
| Water SCHEMBL30296841 | 0.98 | CYP19A1 (0.39) | CYP19A1ADRA2AADRA1AMAPTBLM | |
| Formaldehyde SCHEMBL26919435 | 0.96 | CYP19A1 (0.38) | CYP19A1ADRA2AADRA1AMAPTBLM | |
| SCHEMBL25445590 | 0.89 | CYP19A1 (0.50) | CYP19A1ADRA2AADRA1AALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4604743-A1 | FORMULATED FOOD PRODUCTS | VitaKey Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4566598-A1 | COMPOSITIONS PROVIDING SGLT2I AND BHB ACTIVITY AND METHODS OF USE TO TREAT HUMAN DISEASE | ZoSaLa Pharma, Inc (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250120425-A1 | Combinations of Ketogenic Supplements for Rapid and Sustained Blood Ketone Levels in Dieters and Patients | ZARPAS STEPHEN MICHAEL (US) | 2025-04-17 | — | — | US | claimed |
| CN-119751253-A | Continuous flow synthesis method of ketoester | 苏州满元生物科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| WO-2024086307-A1 | FORMULATED FOOD PRODUCTS | VITAKEY INC. (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2024086311-A1 | FORMULATED TASTANT COMPOSITIONS | VITAKEY INC. (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2024086306-A1 | FORMULATED FOOD PRODUCTS | VITAKEY INC. (US) | 2024-04-25 | — | — | WO | claimed |
| US-20240074459-A1 | KETONE BEVERAGE CONTAINING A SLOW CARBOHYDRATE | KETONEAID, INC. | 2024-03-07 | — | — | US | claimed |
| US-20230295672-A1 | PROCESS FOR PRODUCING (R)-3-HYDROXYBUTYL (R)-3-HYDROXYBUTYRATE | UNIV OXFORD INNOVATION LTD (GB) | 2023-09-21 | — | — | US | claimed |
| US-20230157323-A1 | KETONE BEVERAGE CONTAINING A SLOW CARBOHYDRATE | KETONEAID, INC. | 2023-05-25 | — | — | US | claimed |
| US-20230143566-A1 | KETO ESTER COMPOSITIONS AND METHODS FOR USING SAME | Operade LLC | 2023-05-11 | — | — | US | claimed |
| US-20210015730-A1 | COMPOUND FOR USE IN PROTECTING SKIN | GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF OF HEALTH AND HUMAN SERVICES | 2021-01-21 | — | — | US | claimed |
| US-20160030314-A1 | COMPOUND FOR USE IN PROTECTING SKIN | GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-04 | — | — | US | claimed |
| EP-2968091-A1 | COMPOUND FOR USE IN PROTECTING SKIN | Tdeltas Limited (GB) | 2016-01-20 | — | — | EP | claimed |
| WO-2014139599-A1 | COMPOUND FOR USE IN PROTECTING SKIN | TDELTAS LIMITED (GB) | 2014-09-18 | — | — | WO | claimed |
| CN-122079799-A | Emodin modified amine curing agent, preparation method thereof, long-acting anti-corrosion coating based on body rust conversion, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260137645-A1 | HIGHLY PURIFIED (R)-3’-HYDROXYBUTYL (R)-3’-HYDROXYBUTYRATE AND (R)-3-HYDROXYBUTYRATE AND COMBINATIONS WITH THERAPEUTICS | Ketone Catalyst Innovations, LLC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2010021766-A1 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2010-02-25 | — | — | WO | disclosed |
| US-20080287372-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | ACCERA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACCERA, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295672-A1 | PROCESS FOR PRODUCING (R)-3-HYDROXYBUTYL (R)-3-HYDROXYBUTYRATE | HCAR3, HSD17B12, HSD17B10 | CYP19A1 697/4885ADRA2A 926/4885ADRA1A 866/4885 |
| US-20080287372-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | CPT1B, ACADM, ACAA2 | CYP19A1 2006/4885ADRA2A 2002/4885ADRA1A 2038/4885 |
| US-20230143566-A1 | KETO ESTER COMPOSITIONS AND METHODS FOR USING SAME | KHK, SI, MGAM | CYP19A1 680/4885ADRA2A 3381/4885ADRA1A 2594/4885 |
| US-20260137645-A1 | HIGHLY PURIFIED (R)-3’-HYDROXYBUTYL (R)-3’-HYDROXYBUTYRATE AND (R)-3-HYDROXYBUTYRATE AND COMBINATIONS WITH THERAPEUTICS | IL1B, HADHB, TNF | CYP19A1 2464/4885ADRA2A 2468/4885ADRA1A 2206/4885 |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACHE, CHAT, BACE1 | CYP19A1 2201/4885ADRA2A 71/4885ADRA1A 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.